OXFORD, UK, April 11th, 2014

PharmaVentures is pleased to announce that it has been appointed by Novartis as advisors on the future options for its UK Horsham site. These options could include reusing part of the site as a science or business park, thereby creating a legacy with the possibility of creating some highly skilled jobs for the area in the future. PharmaVentures will provide expert advice on the feasibility of doing this, and to help identify potential partners.

See the Novartis press release here.

Dr Fintan Walton, Chief Executive, PharmaVentures, said “The Novartis Horsham site is a perfect location for a high technology park. Novartis has built state of the art facilities, suitable for pharmaceutical / life science or other high technology businesses. With such high quality facilities, we expect interest from both universities and research institutes.” Dr Walton added “The site would also be ideal as a business park as Horsham is an attractive location due to its strong international links through Gatwick airport and its proximity to London.” 

OXFORD, UK, December 12^th 2013

PharmaVentures is pleased to announce the appointment of expert industry executive Nigel Trim as an associate to significantly enhance PharmaVentures Corporate Advisory offering to the CRO space. 

Over the last 30 years, Nigel has worked extensively across Europe, USA, CEE and South East Asia in the CRO and healthcare industry. Nigel has worked across multiple therapy areas within the pharmaceutical, biotechnology and medical device sectors and brings strategic and operational expertise to the team.

Nigel said “I am excited to be joining PharmaVentures. They already have an impressive track record as advisors and I very much look forward to helping them build upon this at a particularly exciting time in the CRO sector.”  

Nigel has extensive experience in M&A, integration, and creating and managing growth, having successfully built and sold several of his own companies, including Matrix Contract Research. He has also held several senior positions in international contract research organisations, most recently working as Managing Director of Venn Life Sciences. Prior to that, Nigel held the position of European Managing Director of Novella Clinical. 

Fintan Walton, CEO, PharmaVentures Ltd said “We are delighted to welcome Nigel to the PharmaVentures team. We continue to advise many companies in the CRO sector building on our successful role in the 10-year strategic deal between Sanofi and Covance in 2010. Nigel’s expertise in this complex and evolving field will deliver significant additional benefits for our clients.”

OXFORD, UK, September 30th, 2013

PharmaVentures is pleased to announce that it has acted as exclusive M&A advisor to NanoSight in the successful sale of the company to Malvern Instruments, a Spectris plc company. Malvern completed the acquisition on 30th September 2013.

NanoSight’s business is based upon its unique Nanoparticle Tracking Analysis (NTA) instrumentation and software technology and their application across life science and non-life science research. The acquisition follows exceptional year-on-year revenue growth for NanoSight with the company being named as one of 100 fastest growing tech companies in Britain in 2013.

This successful sale also builds on PharmaVentures reputation and success in the M&A field.

Fintan Walton, CEO, PharmaVentures Ltd said: “PharmaVentures is delighted to have worked with NanoSight to find the ideal acquirer who can take the company and its unique technology to next level.”

Adrian Dawkes, VP, who led the transaction team at PharmaVentures added: “This is a fantastic outcome for NanoSight as it will expand their presence in existing markets and give access to previously untapped regions via Malvern’s established presence and respected brand.”

Over the past 21 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.

PharmaVentures acts as Exclusive Advisor on the sale of a majority stake in Doğu Tip, a Turkish Diagnostic Imaging Services company, to Techno Group Investment Holdings, a Gulf Capital portfolio company

OXFORD, UK, April 11th, 2013

PharmaVentures is pleased to announce that Techno Group Investment Holdings, a portfolio company of Gulf Capital, has acquired 100% of Doğu Tip, a Turkish provider of outsourced diagnostic imaging services, with a subsequent allocation of 25% incentive shares to the management.

PharmaVentures, a leading life science and healthcare advisory firm, was advisor to Doğu Tip and its shareholders.

Techno Group is the leading provider of diagnostic imaging services in the MENA region.  Gulf Capital is a leading MENA private equity firm based in Abu Dhabi with close to $2 billion in assets under management.

PharmaVentures CEO, Dr Fintan Walton said, “This deal marks another step in our increased success in M&A generally and in cross-border Emerging Market deals specifically.  We are delighted to have worked on this transaction to deliver a successful outcomeon behalf of our client”.

Ping Shek, who was PharmaVentures’ lead advisor on the deal said, “Turkey is a key regional hub with a large growing healthcare market.  We envisage a continuing high level of investment activity there, especially since the government has recently passed new regulations encouraging foreign investment in its healthcare sector.”

Established in 1992, PharmaVentures has worked on over 600 advisory assignments for clients from top global pharmaceutical and healthcare groups to fast growing biotech companies.  In recent years, it has been increasingly active in M&A, working on assignments worldwide.

– Ends-

OXFORD, UK, December 19th, 2012

PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi’s divestment of its Zentiva subsidiary’s production plant in Hlohovec, Slovakia. Under the terms of this agreement, Sanofi will sell to Wood Pharma Holding the production, packaging and distribution part of its Zentiva business covering Active Pharmaceutical Ingredients (APIs) and Drug Products activities. The sale includes transfer of the production facilities and employees. Future co-operation in the purchase of drug products and APIs produced by Wood Pharma Holding in Hlohovec in the next five years has also been agreed.

This divestment follows the 2010 sale of Sanofi’s two European facilities (Porcheville, France and Alnwick, United Kingdom) to Covance where PharmaVentures acted as exclusive advisors to Sanofi.

PharmaVentures continues to strengthen its considerable experience in the M&A field including divestments of manufacturing and R&D businesses. Fintan Walton, CEO, PharmaVentures Ltd said: “PharmaVentures is delighted to have worked with Sanofi again in finding a new buyer for one of their facilities. This is a fantastic outcome for the Hlohovec site and for the Slovakian Pharmaceutical industry as a whole. Not only does this deal safeguard jobs at Hlohovec, but it offers the prospect of expansion of the existing business and further job opportunities for the region.”

Over the past 21 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.

– ends –

Oxford, UK, October 18th,  2012

PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing PharmaVentures’ corporate finance capabilities and offerings to the global healthcare and investment communities.

Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer says “We are delighted to welcome Stephen to PharmaVentures. Stephen has an impressive track record in investment banking and he brings a wealth of experience in private and public markets that will assist our clients with their deal making and Stephen’s addition to PharmaVentures will therefore be of great benefit.”

Stephen has previously worked with WG Partners, Matrix Corporate Capital, Elixir Securities, Commerzbank, Teather & Greenwood and Evaluate Pharma Plc. He has a BSc from Nottingham University and PhD from Cambridge University.

– ends –